Lomustine + Vincristine + Cisplatin + Cyclophosphamide + Mesna + Vincristine
Phase 1Terminated 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Medulloblastoma
Conditions
Medulloblastoma
Trial Timeline
Apr 4, 2017 → Nov 9, 2018
NCT ID
NCT02212574About Lomustine + Vincristine + Cisplatin + Cyclophosphamide + Mesna + Vincristine
Lomustine + Vincristine + Cisplatin + Cyclophosphamide + Mesna + Vincristine is a phase 1 stage product being developed by Brain Biotech for Medulloblastoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT02212574. Target conditions include Medulloblastoma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02212574 | Phase 1 | Terminated |
Competing Products
9 competing products in Medulloblastoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LY2940680 + LY2940680 | Eli Lilly | Phase 1 | 33 |
| LDE225 + TMZ | Novartis | Phase 2 | 52 |
| LDE225 | Novartis | Phase 1/2 | 41 |
| Modified Measles Virus + Modified Measles Virus Lumbar Puncture | Brain Biotech | Phase 1 | 25 |
| CX 4945 | Brain Biotech | Phase 1/2 | 33 |
| SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years + SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥1 and <10 years + SurVaxM for patients with non-relapsed DIPG post radiation-therapy ages ≥1 and ≤21 years | Brain Biotech | Phase 1 | 25 |
| PEP-CMV | Brain Biotech | Phase 1 | 25 |
| Apatinib Combined With Temozolomide and Etoposide Capsules | Brain Biotech | Phase 2 | 44 |
| Irinotecan + Temozolomide + Bevacizumab + Omburtamab I-131 + Liothyronine + SSKI + Dexamethasone + Antipyretic + Antihistamine + anti-emetics | Brain Biotech | Phase 2 | 44 |